Fluorinated diaminobutane compounds in vivo are inhibitors of gamma-aminobutyric acid transaminase and have the following formula: ##STR1## wherein: R.sub.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, or phenyl-(C.sub.1 -C.sub.4 alkyl); R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl-(C.sub.1 -C.sub.4 alkyl), or R.sub.4, where R.sub.4 is as defined below; R.sub.3 represents hydrogen, or, except when R.sub.2 represents R.sub.4, R.sub.4, where R.sub.4 is as defined below; each R.sub.4, independently, represents C.sub.2 -C.sub.5 alkylcarbonyl, phenylcarbonyl, phenyl-(C.sub.1 -C.sub.4 alkyl) carbonyl, or an aminocarboxylic acid residue derived by removal of an hydroxy group from the carboxy moiety of an L-aminocarboxylic acid; and p represents 1 or 2, and pharmaceutically acceptable acid addition salts thereof.
申请人:GlaxoSmithKline Intellectual Property
Development Ltd
公开号:EP3652179A1
公开(公告)日:2020-05-20
US4435425A
申请人:——
公开号:US4435425A
公开(公告)日:1984-03-06
[EN] INHIBITORS OF LEUCINE RICH REPEAT KINASE 2<br/>[FR] INHIBITEURS DE LA KINASE 2 À RÉPÉTITION RICHE EN LEUCINE
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2019012093A1
公开(公告)日:2019-01-17
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).